Inclusion Criteria:

1. Histologically identified adenocarcinoma of the prostate by minimum 6 core prostate biopsy.
2. Serum PSA </= 10 ng/mL before prostate biopsy
3. Less than 50% of samples from one side of the prostate positive for prostate cancer.
4. No greater than 50% of a single core total length occupied by prostate cancer.
5. No dominant Gleason 4 component. (e.g.; 4+X is not allowed, but X+4 is eligible)
6. No Gleason 5 component (primary, secondary or tertiary).
7. Subjects may have contralateral positive prostate biopsy in a single core within the eligibility biopsy so long as the involvement of this core is 2mm or less and no Gleason 4 or Gleason 5 pattern exists. This is considered to be Non-Dominant (Contralateral) Tumor Burden and is not exclusionary.

Exclusion Criteria:

1. Medical History or Concurrent Disease which in the investigators mind places the patient at significant preoperative risk or for which the investigator does not feel this therapy is appropriate. Investigator believes subject is unwilling or unable to comply with study protocol requirements.
2. AUASI (American Urologic Association Symptom Index) score >/=20
3. Active urinary tract infection
4. Active treatment with anticoagulant/anti-platelet agent that cannot be safely stopped at the time of prostate biopsy and cryotherapy.
5. Medical or surgical castration initiated before or after the eligibility biopsy.
6. Patient is unable to provide informed consent.
7. Patients will undergo base line bone scan prior to cryoablation to evaluate for regions of abnormal uptake before therapeutic intervention.

Metastatic disease by bone scintigraphy is exclusionary.